Landscape Capital Management L.L.C. Sells 68,638 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

Landscape Capital Management L.L.C. decreased its holdings in Hims & Hers Health, Inc. (NYSE:HIMS) by 25.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 198,019 shares of the company’s stock after selling 68,638 shares during the quarter. Hims & Hers Health accounts for about 0.5% of Landscape Capital Management L.L.C.’s investment portfolio, making the stock its 27th largest position. Landscape Capital Management L.L.C. owned approximately 0.09% of Hims & Hers Health worth $4,788,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. SlateStone Wealth LLC grew its stake in shares of Hims & Hers Health by 4.0% during the 4th quarter. SlateStone Wealth LLC now owns 10,640 shares of the company’s stock valued at $257,000 after acquiring an additional 413 shares during the period. Blume Capital Management Inc. lifted its stake in Hims & Hers Health by 100.0% in the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after purchasing an additional 600 shares in the last quarter. Harbour Investments Inc. lifted its position in shares of Hims & Hers Health by 18.8% in the fourth quarter. Harbour Investments Inc. now owns 5,269 shares of the company’s stock worth $127,000 after buying an additional 833 shares in the last quarter. Stonekeep Investments LLC raised its holdings in shares of Hims & Hers Health by 5.5% during the 4th quarter. Stonekeep Investments LLC now owns 16,952 shares of the company’s stock worth $410,000 after acquiring an additional 882 shares in the last quarter. Finally, LPL Financial LLC raised its stake in Hims & Hers Health by 1.0% during the fourth quarter. LPL Financial LLC now owns 97,958 shares of the company’s stock valued at $2,369,000 after purchasing an additional 980 shares in the last quarter. Institutional investors own 63.52% of the company’s stock.

Insiders Place Their Bets

In related news, insider Michael Chi sold 7,259 shares of the stock in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $24.07, for a total value of $174,724.13. Following the completion of the transaction, the insider now directly owns 193,601 shares in the company, valued at approximately $4,659,976.07. This represents a 3.61 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Soleil Boughton sold 268,932 shares of the company’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $27.75, for a total transaction of $7,462,863.00. Following the completion of the transaction, the insider now directly owns 169,803 shares in the company, valued at $4,712,033.25. The trade was a 61.30 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 1,064,954 shares of company stock valued at $37,984,259 in the last 90 days. 17.71% of the stock is owned by insiders.

Hims & Hers Health Price Performance

Shares of NYSE HIMS opened at $27.99 on Friday. Hims & Hers Health, Inc. has a 12 month low of $11.20 and a 12 month high of $72.98. The firm’s 50 day simple moving average is $39.92 and its 200-day simple moving average is $29.77. The stock has a market capitalization of $6.22 billion, a price-to-earnings ratio of 63.60 and a beta of 1.37.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.02. The business had revenue of $481.14 million for the quarter, compared to analyst estimates of $494.56 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. Analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have commented on the stock. Citigroup reaffirmed a “sell” rating and set a $27.00 price objective on shares of Hims & Hers Health in a research note on Thursday, March 6th. BTIG Research assumed coverage on shares of Hims & Hers Health in a report on Tuesday, January 7th. They issued a “buy” rating and a $35.00 price target for the company. Truist Financial upped their price objective on Hims & Hers Health from $24.00 to $39.00 and gave the stock a “hold” rating in a research note on Wednesday, February 26th. Bank of America raised their target price on shares of Hims & Hers Health from $21.00 to $22.00 and gave the company an “underperform” rating in a research note on Tuesday, March 18th. Finally, Needham & Company LLC boosted their price target on Hims & Hers Health from $31.00 to $61.00 and gave the stock a “buy” rating in a research note on Tuesday, February 25th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $37.31.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.